Patents by Inventor Dayong Zhai

Dayong Zhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic compounds and uses thereof
    Patent number: 11981684
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: May 14, 2024
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
    Publication number: 20240140964
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: July 28, 2023
    Publication date: May 2, 2024
    Applicant: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS
    Publication number: 20240033266
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
    Type: Application
    Filed: April 24, 2023
    Publication date: February 1, 2024
    Inventors: Wei DENG, Dayong Zhai, Laura Rodon, Brion W. Murray, Jingrong J. Cui
  • COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS
    Publication number: 20230398119
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
    Type: Application
    Filed: April 26, 2023
    Publication date: December 14, 2023
    Inventors: Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI, Nathan V. LEE
  • CHIRAL DIARYL MACROCYCLES AND USES THEREOF
    Publication number: 20230346786
    Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.
    Type: Application
    Filed: August 15, 2022
    Publication date: November 2, 2023
    Inventors: Jingrong J. CUI, Yishan LI, Evan W. ROGERS, Dayong ZHAI, Wei DENG, Zhongdong HUANG
  • MACROCYCLES FOR USE IN TREATING DISEASE
    Publication number: 20230322806
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: October 12, 2023
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Combination therapy involving diaryl macrocyclic compounds
    Patent number: 11666574
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 6, 2023
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Wei Deng, Dayong Zhai, Laura Rodon, Brion W. Murray, Jingrong J. Cui, Nathan V. Lee
  • Combination therapy involving diaryl macrocyclic compounds
    Patent number: 11654145
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 23, 2023
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Wei Deng, Dayong Zhai, Laura Rodon, Brion W. Murray, Jingrong J. Cui
  • Macrocycles for use in treating disease
    Patent number: 11634433
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: April 25, 2023
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220324879
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Application
    Filed: February 22, 2022
    Publication date: October 13, 2022
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • MACROCYCLIC COMPOUNDS FOR TREATING DISEASE
    Publication number: 20220306652
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Application
    Filed: February 14, 2022
    Publication date: September 29, 2022
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Chiral diaryl macrocycles and uses thereof
    Patent number: 11452725
    Abstract: This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: September 27, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Zhongdong Huang
  • DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES
    Publication number: 20220112213
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: September 27, 2021
    Publication date: April 14, 2022
    Inventors: Jingrong Jean CUI, Yishan Li, Evan W. Rogers, Dayong Zhai
  • Combination therapy involving diaryl macrocyclic compounds
    Patent number: 11291667
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: April 5, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Dayong Zhai
  • Macrocyclic compounds and uses thereof
    Patent number: 11286264
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Macrocyclic compounds for treating disease
    Patent number: 11286265
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 29, 2022
    Assignee: TURNING POINT THERAPEUTICS, INC.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Macrocyclic compounds and uses thereof
    Patent number: 11155563
    Abstract: The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 26, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
  • Macrocycles for use in treating disease
    Patent number: 11142533
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: October 12, 2021
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • MACROCYCLES FOR USE IN TREATING DISEASE
    Publication number: 20210246145
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Application
    Filed: March 26, 2021
    Publication date: August 12, 2021
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS
    Publication number: 20210220364
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
    Type: Application
    Filed: November 25, 2020
    Publication date: July 22, 2021
    Inventors: Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI